Drug Approved for Advanced Kidney Cancer

Drug Approved for Advanced Kidney Cancer
Drug Approved for Advanced Kidney Cancer

FRIDAY, Jan. 27 (HealthDay News) -- Inlyta (axitinib) has been approved by the U.S. Food and Drug Administration to treat advanced renal cell carcinoma in people who haven't responded to another drug. Six medications had been sanctioned previously for advanced kidney cancer, the agency said.

In a study of 723 people with the advanced form of kidney cancer, the most common side effects of Inlyta included diarrhea, high blood pressure, fatigue, loss of appetite, nausea, loss of voice, weight loss, weakness, and constipation.

Among certain patients, Inlyta also caused significant bleeding, which in some cases proved fatal. The FDA also warned that people with hypertension should make sure blood pressure is well controlled before taking the twice-daily drug.

People with untreated brain tumors or gastrointestinal bleeding should not take Inlyta, the FDA said.

The drug is marketed by Pfizer.

More information

Medline Plus has more about renal cell carcinoma.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs